What is B. Riley's Forecast for CATX Q2 Earnings?

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - B. Riley issued their Q2 2025 EPS estimates for shares of Perspective Therapeutics in a report issued on Sunday, June 22nd. B. Riley analyst Y. Zhi anticipates that the company will post earnings per share of ($0.30) for the quarter. B. Riley currently has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. B. Riley also issued estimates for Perspective Therapeutics' Q3 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.30) EPS.

Other equities research analysts have also recently issued reports about the stock. Cantor Fitzgerald raised shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Perspective Therapeutics in a research report on Monday, March 31st. Brookline Capital Management raised shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Thursday, March 6th. Finally, Wedbush reissued an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Monday. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $12.56.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock traded up $0.14 during mid-day trading on Tuesday, hitting $3.76. 4,155,145 shares of the stock were exchanged, compared to its average volume of 1,102,719. The company has a 50-day simple moving average of $2.82 and a 200 day simple moving average of $2.85. Perspective Therapeutics has a twelve month low of $1.60 and a twelve month high of $16.55.

Insider Activity at Perspective Therapeutics

In other Perspective Therapeutics news, Director Robert F. Williamson III purchased 38,145 shares of the business's stock in a transaction that occurred on Monday, March 31st. The shares were purchased at an average price of $2.14 per share, for a total transaction of $81,630.30. Following the completion of the acquisition, the director now owns 108,982 shares of the company's stock, valued at approximately $233,221.48. This represents a 53.85% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.72% of the stock is currently owned by insiders.

Institutional Trading of Perspective Therapeutics

A number of hedge funds have recently made changes to their positions in CATX. Y Intercept Hong Kong Ltd purchased a new stake in shares of Perspective Therapeutics during the fourth quarter valued at approximately $33,000. Aigen Investment Management LP purchased a new stake in shares of Perspective Therapeutics during the fourth quarter valued at approximately $34,000. National Bank of Canada FI raised its stake in shares of Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock valued at $35,000 after purchasing an additional 10,998 shares during the period. ProShare Advisors LLC raised its stake in shares of Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock valued at $49,000 after purchasing an additional 5,011 shares during the period. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in shares of Perspective Therapeutics during the fourth quarter valued at approximately $51,000. Hedge funds and other institutional investors own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.